Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03534323
Title Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

chronic lymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Duvelisib + Venetoclax

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.